VanEck Pharmaceutical ETF
PPH
106 hedge funds and large institutions have $356M invested in VanEck Pharmaceutical ETF in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 39 reducing their positions, and 22 closing their positions.
426% more call options, than puts
Call options by funds: $5.35M | Put options by funds: $1.02M
8.17% more ownership
Funds ownership: 87.97% → 96.14% (+8.2%)
7% less funds holding
Funds holding: 114 → 106 (-8)
30% less capital invested
Capital invested by funds: $510M → $356M (-$154M)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
44% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 39
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$37M |
| 2 |
HF
HRT Financial
New York
|
+$4.78M |
| 3 |
JP Morgan Chase
New York
|
+$3.89M |
| 4 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$3.21M |
| 5 |
WWM
WT Wealth Management
Scottsdale,
Arizona
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$147M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$30.7M |
| 3 |
Goldman Sachs
New York
|
-$19.5M |
| 4 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
-$11.8M |
| 5 |
LPL Financial
San Diego,
California
|
-$5.08M |
PPH Hedge Fund Activity: Q1 2023 in Review
106 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2023, worth a combined $356M — down 30% from $510M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PPH and 14 opened new positions — a net loss of 8 holders — while 39 trimmed existing stakes and 22 added.
The largest buyer was Bank of America, adding an estimated $37M. The largest seller was Phoenix Financial, cutting an estimated $147M.
- 106 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2023, down from 114 in Q4 2022.
- Funds reported $356M of VanEck Pharmaceutical ETF stock for Q1 2023, down 30% quarter-over-quarter.
- 14 funds opened new VanEck Pharmaceutical ETF positions in Q1 2023 and 22 closed out, a net change of -8 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2023 was Bank of America, an estimated $37M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2023 was Phoenix Financial, an estimated $147M sold.
Based on aggregated 13F filings for Q1 2023.